Skip to main content
Supplement ScienceSupplementScience

Types of CBD: Forms & Bioavailability

Evidence:Emerging
·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Forms Comparison

FormBioavailabilityBest For
Full-Spectrum CBD OilModerate (13-19% sublingual)Maximum efficacy — contains trace THC (<0.3%) and other cannabinoids for potential entourage effect
Broad-Spectrum CBD OilModerate (13-19% sublingual)THC-free with entourage — contains other cannabinoids and terpenes but no THC
CBD IsolateModeratePure CBD — 99%+ pure cannabidiol, no other cannabinoids, best for those needing zero THC
CBD Capsules/SoftgelsLow-Moderate (6-15% oral)Consistent dosing — pre-measured doses but lower bioavailability than sublingual oil

Full-Spectrum CBD Oil

Bioavailability: Moderate (13-19% sublingual). Best for: Maximum efficacy — contains trace THC (<0.3%) and other cannabinoids for potential entourage effect.

Broad-Spectrum CBD Oil

Bioavailability: Moderate (13-19% sublingual). Best for: THC-free with entourage — contains other cannabinoids and terpenes but no THC.

CBD Isolate

Bioavailability: Moderate. Best for: Pure CBD — 99%+ pure cannabidiol, no other cannabinoids, best for those needing zero THC.

CBD Capsules/Softgels

Bioavailability: Low-Moderate (6-15% oral). Best for: Consistent dosing — pre-measured doses but lower bioavailability than sublingual oil.

Full CBD Guide

References

  1. Case reportShannon S, Lewis N, Lee H, Hughes S (2019). Cannabidiol in anxiety and sleep: a large case series. Permanente Journal. DOI PubMed
  2. RCTLinares IM, Zuardi AW, Pereira LC, et al. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry. DOI PubMed
  3. RCTZuardi AW, Cosme RA, Graeff FG, Guimarães FS (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of Psychopharmacology. DOI PubMed
  4. ReviewBlessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. DOI PubMed
  5. Meta-analysisHan K, Wang JY, Wang PY, Peng YC (2024). Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis.. Psychiatry research. DOI PubMed
  6. Lo LA, Christiansen AL, Strickland JC, Pistawka CA, et al. (2024). Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC).. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. DOI PubMed
  7. Freeman TP, Craft S, Wilson J, Stylianou S, et al. (2021). Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.. Addiction (Abingdon, England). DOI PubMed
Show 5 more references
  1. Dos Santos MC, da Silva AMP, da Vitória Santos do Nascimento M, da Silva TMS, et al. (2026). The Influence of CBD and THC on Hepatic Enzymes of the Human Cytochrome P450 Complex Family: A Systematic Literature Review.. European journal of drug metabolism and pharmacokinetics. DOI PubMed
  2. Duan S, Liu M, An Z, Zhong Z, et al. (2026). Unlocking the potential: Cannabidiol (CBD) as a promising anti-tumor agent.. Phytomedicine : international journal of phytotherapy and phytopharmacology. DOI PubMed
  3. Gras M, Bearden D, West J, Nabbout R (2024). Efficacy of anti-seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1-related epilepsy: A systematic review.. Epilepsia open. DOI PubMed
  4. Aderinto N, Olatunji G, Kokori E, Ajayi YI, et al. (2024). The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.. European journal of medical research. DOI PubMed
  5. Hindelang P, Scharinger A, Richling E, Walch SG, et al. (2022). Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.. Frontiers in bioscience (Landmark edition). DOI PubMed